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Abstract
Background: MicroRNAs (miRNAs) play critical roles in different pathological processes in-
cluding cancer development and progression. To find novel molecular diagnostic and prognos-
tic markers and promising therapeutic tools for gastric cancer (GC), we aimed to investigate 
the relationship of the expression levels of miR–28–5p or miR–200a–3p with the clinicopath-
ological criteria and to explore their impacts on the progression of human GC. Materials and 
Methods: Quantitative RT–PCR was performed to analyze miR–28 and miR–200a expression 
in 60 GC and 60 non–GC tissue samples. Result: Our results revealed that the expressions 
of miR–200a and miR–28 were significantly downregulated in GC in comparison with non–
GC tissues. Tumors with low miR–28 expression had larger tumor size, more advanced his-
tological grade, and a higher incidence of lymph node and distal metastasis than the tumors 
with high miR–28 expressions. Furthermore, receiver operating characteristic (ROC) analy-
ses demonstrate that the expression of miR–28 is a predictive biomarker allows predicting the 
histological grade, tumor size, and occurrence of nodal and distal metastases. We also found 
a significant inverse association between miR–200a expression and the rate of lymph node 
metastasis (p = 0.010, r = –0.334). Conclusion: Our findings suggest that the miR–28 and 
miR–200a have tumor–suppressor functions and may be considered as potential biomarkers 
for gastric cancer diagnosis and prognosis.[GMJ.2019;8:e1329] DOI: 10.31661/gmj.v8i0.1329
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Introduction
As the fourth most common cause of ma-lignancies, gastric cancer (GC) represents 
the second reason of cancer death globally [1]. 
Most GC patients are identified at advanced 
stages of the disease, with local invasion or tu-
mor metastasis and poor overall survival rate. 
However, if GC is detected in early stage, the 
survival rate of patients increases to over 90% 
[2, 3]. The prognosis of GC is influenced by 
several biological variables and the combina-
tion of molecular alterations may contribute 
to the aggressive progression of GC [4, 5]. 
However, the precise molecular mechanisms 
involved in the progression and carcinogene-
sis of GC have not yet been completely char-
acterized. Therefore, it is extremely necessary 
to identify novel molecular diagnostic and 
prognostic markers to improve the clinical 
prognosis of GC patients as well as to enhance 
the efficiency of treatment strategies.MicroR-
NAs (miRNAs) are a category of endogenous, 
small (18–24 nucleotides), noncoding RNAs 
that primarily function as post-transcription-
al regulators of protein-coding genes through 
binding to the untranslated regions (UTRs) at 
the 3’end of downstream mRNAs [6]. Recent 
studies have strongly supported the notion that 
microRNAs have critical roles in fundamen-
tal biological events, comprising cell prolif-
eration, differentiation, and apoptosis, as well 
as different pathological processes such as 
carcinogenesis, tumor angiogenesis, and inva-
sion [7-9]. More than fifty percent of microR-
NA–coding genes are anchored in the fragile 
regions as well as in genomic are as affected in 
various cancers [10], proposing the impacts of 
miRNAs in the pathogenesis of human cancer. 
Several tumor–associated miRNAs have been 
shown to be dysregulated in GC. For example, 
in a systematic review of 14 miRNA expres-
sion profiling studies, Shrestha et al. reported 
352 miRNAs which dissimilarly expressed in 
participants with and without GC [11]. They 
introduced some of the candidate miRNAs as 
efficient biomarkers and therapeutic targets in 
human GC.The potential role of miR–28–5p 
and its mechanism have been studied in col-
orectal [12], ovarian [13], and VHL–associ-
ated cancer [14]. Almeida et al. showed that 
mir–28–5p had a remarkably lower expression 
in colorectal tumor tissues compared with nor-
mal colon tissues. In addition, upregulation 
of mir–28–5p could increase apoptosis and 
reduce cell proliferation and migration in the 
colorectal cancer cells [12]. A growing body 
of evidence has shown that the miR-200 fami-
ly, consisting five members (miR–200a, miR–
200b, miR–200c, miR–141, and miR–429), 
may serve as tumor-suppressor miRNAs and 
replacement of these miRNAs has been indi-
cated as a new therapeutic strategy in multiple 
types of cancers [15-17]. miR–200a functions 
as a suppressor of tumor cell growth, epithe-
lial–mesenchymal transition (EMT) and can-
cer invasion/metastasis [18-20]. These obser-
vations led us to evaluate the expressions of 
miR–28–5p and miR–200a–3p in gastric ad-
enocarcinoma, and to determine their clinico-
pathological significance. Our findings support 
the interpretation that upregulation of tumor 
suppressor miR–28 and miR–200a can be an 
intriguing possibility for future GC treatment.
Materials and Methods
1. Patients and Sample Collection
This case/control study was performed on the 
patients with gastric adenocarcinoma (n=60) 
referring to Madani and Imam Reza Hospi-
tals, Tabriz, Iran. Fresh endoscopic biopsies 
taken from 60 non-GC patients were also 
prepared as control samples. The tissue spec-
imens were immediately frozen in liquid ni-
trogen as soon as possible, and subsequently 
stored at –80°C till further analysis. One piece 
of each sample was fixed with 4% parafor-
maldehyde and used for histological analysis.
2. Quantitative Reverse Transcription PCR 
Analysis (qRT–PCR)
2.1. qRT–PCR Analysis of miR–28 and miR–
200a Expressions
The relative expression levels of miR–28–5p 
and miR–200a–3p in both GC and non–GC 
tissue samples were analyzed by qRT–PCR 
method. TriPure Isolation Reagent (Roche, 
Germany) was applied to extract total RNA 
by physical disruption and Phenol/Chloroform 
methods. RNA from each tissue sample was 
reverse–transcribed to complementary DNA 
(cDNA) by using the miRCURY LNATM Uni-
versal cDNA synthesis kit (Cat No. #203301) 
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on Thermocycler (Eppendorf). Briefly, 100 ng 
RNA was mixed with 2 μl of 5× reaction buf-
fer, 1 μl reverse transcriptase, and up to 4.5 μl 
of nuclease-free water, incubated in PCR ma-
chine for 60 min at 42˚C, 5 min at 95˚C and 
then, immediately cooled to 4°C. The resultant 
cDNA was diluted 20 times, and served as a 
template for miRNA qRT–PCR using miR-
CURY LNATMUniversal RT miRNA PCR 
SYBR® Green kit (Exiqon, Denmark) and 
primer sets (Product No. 204322 and 204707, 
Exiqon, Vedbaek, Denmark). Four microliters 
of diluted cDNA were used in each real-time 
PCR reaction, which contained 1μL PCR prim-
er set and 5 μL PCR Master Mix to make a fi-
nal volume of 10 μL. Amplification carried out 
under the following conditions: initial denatur-
ation at 95 °C for 10 min, 40 cycles at 95°C for 
10 seconds and then 60°C for 1 minute. The 
primer sequences were as follows: hsa-miR-
28-5p (5′-AAGGAGCUCACAGUCUAUU-
GAG-3′); hsa-miR-200a-3p (5′-CATCTTAC-
CGGACAGTGCTGGA-3′); hsa-miR-103 
(5′-AGCAGCATTGTACAGGGCTATGA-3′).
2.2. Normalization Method 
The comparative CT method was performed 
to measure the relative expression levels of 
miR–28 and miR–200a in the GC and non–
GC biopsy samples. All qRT–PCR data were 
normalized after subtracting the CT values of 
these miRNAs from that of miR–103 (Cat No. 
#204030) as an internal control (2–ΔCT meth-
od, ΔCT = CTmiR–28 or miR–200a –CtmiR–103). Each 
measurement was performed in triplicate.
2.3. Ethical Statements
This project was reviewed and approved at 
the Research Ethics Committee of Tabriz 
University of Medical Sciences (Reference 
number: 1394.618). All participants were 
asked to sign a written consent describing the 
study aims and the subsequent procedures.
2.4. Statistical Analysis
The Mann–Whitney analysis was employed to 
evaluate the differential expression of miR–28 
and miR–200a between GC and non–GC spec-
imens. The statistical significances among 
clinicopathological characteristics and both 
miR–28 and miR–200a expression levels were 
assessed by Chi-square (χ2) test. All statistical 
tests were carried out by GraphPad Prism ver-
sion 6 (GraphPad Software Inc., San Diego, Cal-
ifornia) or SPSS software version 11.0 (SPSS 
Inc., Chicago, Illinois). P value of less than 
0.05 was considered as statistically significant.
Result
1. Demographic Information
There were 40 males and 20 females in the 
gastric cancer group with the average age 
of 68.3 ± 12.9 years, ranging from 31 to 93 
years. In non-GC patients, the mean age 
was 61.8 ± 15.1 years, the range of 23–84 
years. The clinicopathological data of the 
participants are represented in Table 1.
2. miR–28 and miR–200a were Downregulat-
ed in Gastric Cancer Patients
To explore the roles of the miR–28–5p and 
miR–200a–3p in the GC, the expression levels 
of these miRNAs were assessed by quantita-
tive RT–PCR in all tissue samples. Our results 
showed that the expression levels of miR–28 
(GC vs. non–GC: 16.877 ± 2.603 vs 64.329 ± 
Table 1. Summary of Clinicopathological Features 
of Patients withGgastric Cancer
Clinical Pathological
features No. of Patients (%)
Sex
Male 40 (66.7)
Female 20 (33.3)
Age (year)
< 65 20 (33.3)
≥65 40 (66.7)
Tumor size (cm)
< 5 37 (61.7)
≥5 23 (38.3)
Histologic grade of 
differentiation
Well 14 (23.3)
Moderate 36 (60)
Poor 10 (16.7)
Lymph node metastasis
Present 32 (53.3)
Absent 28 (46.7)
Distal metastasis
Present 11 (18.3)
Absent 49 (81.7)
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4.885, P< 0.001) and miR–200a (GC vs non–
GC: 0.468 ± 0.105 vs 2.683 ± 0.293, P< 0.001) 
in human GC tissues were significantly lower 
than those in non–GC tissues (Figure 1). To de-
termine the relationship between clinicopath-
ological criteria and miRNAs expression, the 
median values of miR–28 (7.790) and miR–
200a (0.227) expression were used as cutoff 
points for classifying all 60 patients with gas-
tric adenocarcinoma into miR–28–low/high 
and miR–200a–low/high groups, respectively. 
3. Downregulation of miR–28 Associates with 
Aggressive Progression of Gastric Cancer
The association between clinicopathological 
features and miR–28 expression is summa-
rized in Table 2. GC patients with low expres-
sion levels of miR–28 had greater tumor size (p 
= 0.001), higher histologic grade (p = 0.004), 
and more frequently positive lymph node 
(p<0.001) and distal metastasis (p= 0.003). 
However, there were no significant correla-
tions between miR–28 expression and other 
clinicopathologic variables such as sex, age, 
and smoking status (all p>0.05). Further statis-
tical analysis showed considerable differences 
in miR–28 level between poor (high grade) 
and moderate (intermediate grade), as well as 
between well (low grade) and poorly differen-
tiated tumors (all p > 0.05). Nevertheless, no 
significant difference was found in miR–28 
expression between well and moderately dif-
ferentiated adenocarcinomas (p> 0.05).Re-
ceiver operating characteristic (ROC) curve 
was also applied to survey the predictive value 
of miR–28 level in the GC patients for clinico-
pathologic criteria. ROC results suggested that 
miR–28 had the capability to predict tumor 
size, histologic grade and occurrence of lymph 
node and distal metastases (Table 3). The ex-
pression of miR–28 and tumor size yielded a 
significant AUC of 0.735 (95 % confidence in-
terval 0.590–0.880; p=0.002) with a sensitivity 
of 83.8 %, specificity of 73.9 %, and optimal 
cutoff point of 4.11 (Figure 2a). AUC for the 
histological grade was 0.913 (95 % confidence 
interval 0.841–0.985; p<0.001) with an opti-
mal cutoff point of 3.04, where the correspond-
ing specificity and sensitivity were 100 % and 
84.0 %, respectively (Figure 2b). The optimal 
cutoff values of miR–28 were 6.32 and 3.09 
for predicting lymph node and distal metasta-
sis with AUC values of 0.773 (95 % confidence 
interval 0.649–0.897; p<0.001) and 0.844 (95 
% confidence interval 0.705–0.983; p<0.001), 
respectively. The corresponding sensitivi-
ty and specificity were 71.9 and 85.7%, and 
90.9 and 81.6%, respectively (Figure 2c, d).
4. Association Between Clinicopathological 
Criteria and miR–200a Level in gastric Ade-
nocarcinoma
To assess whether the downregulation of 
miR-200a expression in the GC tissues was 
associated with clinicopathologic features, the 
Chi-square (χ2) test was applied. The statis-
tical analysis showed that the miR–200a ex-
pression only had an association with lymph 
node metastasis (p = 0.010). As shown in 
Table 2, the low levels of miR–200a ex-
pression were 65.6% (21 of 31) and 32.1% 
(9 of 28) in the patients with and with-
Figure 1.miR–28and miR–200a expression in GC and non –GC tissue samples detected by quantitative reverse transcription–polymerase 
chain reaction (qRT–PCR) analysis.
GC: Gastric cancer, ***: p< 0.001.
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Table 2. Association of miR-28 and miR–200a Expressions with Various Clinicopathologicalcriteria of Pa-
tients With Gastric Cancer
Clinical Pathological
Criteria
miR–28 Expression
P value
miR–200a Expression
P value
Low (%) High (%) Low (%) High (%)
Sex 0.587 0.103
Male 21 (52.5) 19 (47.5) 23 (57.5) 17 (42.5)
Female 9 (35.0) 11 (65.0) 7 (35.0) 13 (65.0)
Age (years) 0.277 0.587
< 65 8 (40.0) 12 (60.0) 11 (55.0) 9 (45.0)
≥65 22 (55.0) 18 (45.0) 19 (47.5) 21 (52.5)
Tumor size (cm) 0.001 0.065
< 5 12 (32.4) 25 (67.6) 15 (40.5) 22 (59.5)
≥5 18 (78.3) 5 (21.7) 15 (65.2) 8 (34.8)
Histologic grade of 
differentiation
0.001 0.492
Well/ Moderately 20 (40.0) 30 (60.0) 24 (48.0) 26 (52.0)
Poor 10 (100.0) 0 (0.0) 6 (60.0) 4 (40.0)
Lymph node 
metastasis
<0.001 0.010
Present 23 (71.9) 9 (28.1) 21 (65.6) 11 (34.4)
Absent 7 (25.0) 21 (75.0) 9 (32.1) 19 (67.9)
Distal metastasis 0.003 0.741
Present 10 (90.9) 1 (9.1) 5 (45.5) 6 (54.5)
Absent 20 (40.8) 29 (59.2) 25 (51.0) 24 (49.0)
Smoking status 0.756 0.351
Smoker 7 (53.8) 6 (46.2) 8 (61.5) 5 (38.5)
Never–smoker 23 (48.9) 24 (51.1) 22 (46.8) 25 (53.2)
Table 3. AUCs for ROC Curve Corresponding to the Diagnostic values of miR–28 and miR–200a in Gastric 
Cancer.
Parameter
miR–28 miR–200a
AUC
Standard 
Error
95 % C.I.
P 
value
AUC
Standard 
Error
95 % C.I.
P 
value
Tumor size 0.735 0.074 0.590–0.880 0.002 0.696 0.070 0.559–0.833 0.011
Histologic 
grade
0.913 0.037 0.841–0.985 <0.001 0.659 0.080 0.502–0.816 0.115
Lymph node 
metastasis
0.773 0.063 0.649–0.897 <0.001 0.695 0.071 0.556–0.835 0.010
Distal 
metastasis
0.844 0.071 0.705–0.983 <0.001 0.509 0.099 0.315–0.703 0.924
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Figure 2. Diagnostic values of miR–28 and miR–200a in GC. Expression of miR–28 was applicable molecular biomarker for prediction of 
tumor size (a), histological grade (b) and occurrence of lymph node (c) and distal metastasis (d). In addition, ROC curve analysis showed 
the potential of miR–200a level to predict tumor size (e) and occurrence of lymph node metastasis (f) in gastric adenocarcinoma.
GC: gastric cancer, ROC: receiver operating characteristics.
out lymph node metastasis, respectively. 
Indeed, in GC tissue samples, the miR–200a 
expression was downregulated when lymph 
node metastasis was present. However, there 
were no remarkable associations among 
miR–200a levels and sex (p = 0.103), age 
(p = 0.587), tumor size (p = 0.065), histo-
logic grade (p = 0.103), distal metastases (p 
= 0.741), or smoking status (p = 0.351). The 
prognostic significance of miR-200a was elu-
cidated with ROC curves. Our results showed 
that miR–200a had the ability only to predict 
tumor size and lymph node metastasis (Table 
3). The AUC values were 0.696 (95 % con-
fidence interval 0.559–0.833; p=0.011) and 
0.695 (95 % confidence interval 0.556–0.835; 
p=0.010) with cutoff points of 0.334 and 
0.444, where the corresponding sensitivity 
and specificity were 51.4 % and 87.0 %, and 
90.6 % and 53.6 %, respectively (Figure 2e, f).
Discussion
Previous studies strongly support the notion 
that miRNAs, as post–transcriptional regula-
tory molecules, can target up to one–third of 
human coding genes and act as oncogenes or 
tumor suppressor genes [21, 22]. Thus, iden-
tification of novel and differentially expressed 
miRNAs should be considered as a topic of in-
tense research in the cancer diagnosis, progno-
sis, and therapy. In our research, we aimed to 
investigate the expression level of miR–28 and 
miR–200a in the patients with gastric cancer 
and to determine their relationship with clin-
icopathologic parameters. Our results showed 
that miR–28 and miR–200a expressions in the 
GC tissue samples were considerably lower 
compared to noncancerous samples. Further-
more, the reduced level of miR–28 was sig-
nificantly relevant to larger tumor sizes, more 
advanced histologic grades, and a higher in-
cidence of lymph node and distal metastases 
in gastric adenocarcinomas. In addition, ROC 
results revealed that the expression of miR–28 
was applicable molecular biomarker for pre-
diction of tumor sizes, histologic grades, and 
occurrence of lymph node and distal metasta-
ses.Based on the tumor tissue and the cell type, 
miRNAs have oncogenic or tumor-suppressor 
6 GMJ.2019;8:e1329
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functions [23-27]. miR–28–5p displays differ-
ential expression patterns and plays diverse 
roles in the development of human cancers 
[12, 13, 28-30]. For example, Xu et al. indi-
cated that miR–28–5p was considerably over-
expressed in ovarian cancer samples compared 
with adjacent non–malignant controls and its 
overexpression could enhance the ovarian 
cancer cell progression, invasion, migration, 
and proliferation [13]. Similarly, in glioma 
cells, Malzkorn et al. showed that miR–28 
level was increased during glioma progression 
in the majority of investigated patients [28]. 
However, miR–28 was significantly downreg-
ulated in breast cancer cells, where it targets 
the 3′UTR of Nrf2 mRNA. In another study, 
downregulation of miR–28 was identified to 
be oppositely correlated with tumor metastasis, 
recurrence, and poor survival of hepatocellu-
lar carcinoma, indicating a tumor–suppressor 
function for this microRNAs [31]. Moreover, 
miR–28–5p was found to be downregulated 
in renal cell carcinomas [30] and colorectal 
tumors [12], while it’s in vitro upregulation 
could reduce invasion, migration, and prolif-
eration of colorectal carcinoma. Accumulating 
evidence suggests that there is heterogene-
ity in miR–28–5p expression in various can-
cers, and investigation of miR–28 expression 
can be considered as a molecular signature to 
identify clinical and pathological prognostic 
factors. Our results also revealed a significant 
negative correlation between the incidence of 
lymph node metastasis and expression level 
of miR–200a. Moreover, ROC curve analy-
sis showed the potential of miR–200a level to 
predict tumor size and occurrence of lymph 
node metastasis in the gastric adenocarcino-
ma. Other studies also showed low levels of 
miR–200a in tumor tissues and cell lines [16, 
18, 19, 32]. Chang et al. found that members 
of the miR-200 family had significantly low-
er expressions in the GC tissues when com-
pared with matched nonmalignant tissues [16]. 
In another study, Sun et al. also found simi-
lar results that miR–200a expression level 
was negatively correlated with tumor metas-
tases in the ovarian tumors [32]. They found 
no remarkable relationship among the miR–
200a level and tumor size, histological type, 
and grade. Gain and loss of function study 
by Pichler et al showed that downregulation 
of miR–200a-3p by using a specific miR–
200a inhibitor led to increased expression of 
EMT–related genes in colorectal cancer cell 
lines [19]. They also demonstrated that low-
er levels of miR–200a were associated with 
poor survival in colorectal cancer patients. 
However, in a different study, the high level 
of serum miR–200a-3p was seen in epithelial 
ovarian tumors, where it correlated with his-
tological subtype and stage [33]. The limita-
tion of our study was that we could not ana-
lyze the association between overall survival 
and the microRNAs expression because it re-
quires patients to be followed up to five years.
Conclusion
Our results highlight the significance of the 
miR–28–5p and miR–200a–3p as potential bio-
markers in the diagnosis and prognosis of gas-
tric adenocarcinoma. These miRNAs may play 
tumor–suppressor functions in the carcinogen-
esis and tumor progression of gastric cancer 
through the regulation of cell proliferation, 
differentiation, tumor angiogenesis, and inva-
sion. However, future investigations are nec-
essary to identify the molecular mechanisms 
of miR–28 and miR–200a in the development 
and progression of gastric adenocarcinoma.
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